Skip to main content
Erschienen in: Journal of Cancer Research and Clinical Oncology 4/2017

19.12.2016 | Original Article – Clinical Oncology

Prognostic impact of tumour burden measured by quantitative real-time PCR from sentinel lymph nodes of melanoma patients: data from 10-year follow-up

verfasst von: Thomas Kurt Eigentler, Joachim Hinderer, Seema Noor, Claus Garbe, Ulrike Leiter

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 4/2017

Einloggen, um Zugang zu erhalten

Abstract

Background

Sentinel node (SN) biopsy is regarded as standard of care for patients (pts) with cutaneous melanoma ≥1.0 mm of thickness. In the recent AJCC classification, findings in the SN are simply classified as positive or negative. In our analyses, we were interested whether quantitative real-time PCR (qRT-PCR) is able to predict disease-free survival (DFS) and overall survival (OS) depending on tumour burden in the SN.

Methods

One hundred and forty-five pts were analysed using qRT-PCR for tyrosinase. Results were analysed using accelerated failure time survival model and cox proportional hazards models using the R statistics framework.

Results

Forty-one pts (28%) were positive according to qRT-PCR. In total, 12 of 41 pts showed tumour deposits in the SN using S100 and/or HMB-45-labelled immunohistochemistry as well. One patient had micrometastases detected by immunohistochemistry staining but failed in the qRT-PCR. After 10 years of follow-up, 34 patients recurred and 27 patients died. Significant differences for DFS and OS were detected for sex, increasing tumour thickness, ulceration of the primary tumour, and metastatic spread in the SN determined by histology as well as qRT-PCR.

Conclusion

Quantitative analyses showed a logarithmic correlation between tumour burden and prognosis. However, as multivariate analyses reveal qRT-PCR was not superior compared to classical histology or immunohistology.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
Zurück zum Zitat Eggermont AM et al (2008) Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet 372:117–126. doi:10.1016/S0140-6736(08)61033-8 CrossRefPubMed Eggermont AM et al (2008) Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet 372:117–126. doi:10.​1016/​S0140-6736(08)61033-8 CrossRefPubMed
Zurück zum Zitat Garbe C, Schadendorf D (2003) Malignes Melanom-neue Daten und Konzepte zur Nachsorge Dtsch Arztebl. International 100:1804–1808 Garbe C, Schadendorf D (2003) Malignes Melanom-neue Daten und Konzepte zur Nachsorge Dtsch Arztebl. International 100:1804–1808
Zurück zum Zitat Gloghini A, Canal B, Klein U, Dal Maso L, Perin T, Dalla-Favera R, Carbone A (2004) RT-PCR analysis of RNA extracted from Bouin-fixed and paraffin-embedded lymphoid tissues. J Mol Diagn JMD 6:290–296CrossRefPubMed Gloghini A, Canal B, Klein U, Dal Maso L, Perin T, Dalla-Favera R, Carbone A (2004) RT-PCR analysis of RNA extracted from Bouin-fixed and paraffin-embedded lymphoid tissues. J Mol Diagn JMD 6:290–296CrossRefPubMed
Zurück zum Zitat Leiter U et al (2016) Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial. Lancet Oncol 17:757–767. doi:10.1016/S1470-2045(16)00141-8 CrossRefPubMed Leiter U et al (2016) Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial. Lancet Oncol 17:757–767. doi:10.​1016/​S1470-2045(16)00141-8 CrossRefPubMed
Zurück zum Zitat Morton DL et al (1992) Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 127:392–399CrossRefPubMed Morton DL et al (1992) Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 127:392–399CrossRefPubMed
Zurück zum Zitat Starz H, Balda BR, Kramer KU, Buchels H, Wang H (2001) A micromorphometry-based concept for routine classification of sentinel lymph node metastases and its clinical relevance for patients with melanoma. Cancer 91:2110–2121CrossRefPubMed Starz H, Balda BR, Kramer KU, Buchels H, Wang H (2001) A micromorphometry-based concept for routine classification of sentinel lymph node metastases and its clinical relevance for patients with melanoma. Cancer 91:2110–2121CrossRefPubMed
Zurück zum Zitat van Akkooi ACJ, de Wilt JH, Verhoef C, Schmitz PI, van Geel AN, Eggermont AM, Kliffen M (2006) Clinical relevance of melanoma micrometastases (<0.1 mm) in sentinel nodes: are these nodes to be considered negative? Ann Oncol 17:1578–1585. doi:10.1093/annonc/mdl176 CrossRefPubMed van Akkooi ACJ, de Wilt JH, Verhoef C, Schmitz PI, van Geel AN, Eggermont AM, Kliffen M (2006) Clinical relevance of melanoma micrometastases (<0.1 mm) in sentinel nodes: are these nodes to be considered negative? Ann Oncol 17:1578–1585. doi:10.​1093/​annonc/​mdl176 CrossRefPubMed
Zurück zum Zitat van Akkooi ACJ et al (2009) Excellent long-term survival of patients with minimal sentinel node tumor burden (<0.1 mm) according to Rotterdam Criteria: a study of the EORTC melanoma group. EJC Suppl 7:576–577CrossRef van Akkooi ACJ et al (2009) Excellent long-term survival of patients with minimal sentinel node tumor burden (<0.1 mm) according to Rotterdam Criteria: a study of the EORTC melanoma group. EJC Suppl 7:576–577CrossRef
Metadaten
Titel
Prognostic impact of tumour burden measured by quantitative real-time PCR from sentinel lymph nodes of melanoma patients: data from 10-year follow-up
verfasst von
Thomas Kurt Eigentler
Joachim Hinderer
Seema Noor
Claus Garbe
Ulrike Leiter
Publikationsdatum
19.12.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Cancer Research and Clinical Oncology / Ausgabe 4/2017
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-016-2323-0

Weitere Artikel der Ausgabe 4/2017

Journal of Cancer Research and Clinical Oncology 4/2017 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.